Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

AIMS: Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials. It is unknown if this relationship holds for total (first and subsequent) events. In the ODYSSEY OUTCOMES trial in patients with recent acute coronary syndrome (ACS), the proprotein convertase subti...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eur Heart J
Hauptverfasser: Szarek, Michael, Bittner, Vera A, Aylward, Philip, Baccara-Dinet, Marie, Bhatt, Deepak L, Diaz, Rafael, Fras, Zlatko, Goodman, Shaun G, Halvorsen, Sigrun, Harrington, Robert A, Jukema, J Wouter, Moriarty, Patrick M, Pordy, Robert, Ray, Kausik K, Sinnaeve, Peter, Tsimikas, Sotirios, Vogel, Robert, White, Harvey D, Zahger, Doron, Zeiher, Andreas M, Steg, Ph Gabriel, Schwartz, Gregory G
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2020
Schlagworte:
Clinical Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724642/
https://ncbi.nlm.nih.gov/pubmed/33051646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa649
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge